Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Furore among rival firms as HPV (human papilloma virus) beats cytology in screening study

This article was originally published in Clinica

Executive Summary

Prompting fierce debate between rival firms, a controversial Lancet study has found that human papilloma virus (HPV- testing is better for cervical cancer screening than the standard Pap cytology test. The findings could have huge connotations, potentially leading to a large-scale switch across Europe from cytology to HPV testing. Cytology (smear) tests would still be used, but in a confirmatory capacity.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel